Lantheus Downgraded to 'Hold' Following $6.7B Acquisition Deal by Curium

In a move reflecting the accelerating consolidation within the radiopharmaceutical sector, Lantheus has agreed to be acquired by its competitor Curium in a cash transaction initially valued at $6.7 billion. Under the deal terms, Lantheus shareholders are set to receive $102.50 per share in cash, supplemented by Contingent Value Rights (CVRs) that could provide up to an additional $12.00 based on sales milestones through 2030. The merger is designed to combine Curium's global manufacturing footprint with Lantheus's established diagnostic business in the U.S. market.

Following the announcement, Cowen & Co downgraded Lantheus from 'Buy' to 'Hold,' noting that the stock's market price has moved close to the $102.50 cash offer. According to analyst reports, the downgrade reflects limited upside potential for retail investors now that the acquisition price has been established. Furthermore, the non-guaranteed nature of the CVR payments has prompted legal scrutiny regarding whether the transaction price is equitable for public shareholders, per market reports.

With current price data unavailable for this session, traders are looking for the stock to stabilize near the offer price as a signal of market confidence in the deal's closure. Regarding broader catalysts, the market remains sensitive to financing conditions following the Fed Interest Rate Decision on July 29, 2026, which maintained rates at 3.75%, as borrowing costs remain a critical factor for large-scale M&A execution.